Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BON NASDAQ:BPTH NASDAQ:PTPI NASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.92+24.7%$1.41$1.14▼$73.75$321K-0.462.02 million shs60.85 million shsBPTHBio-Path$0.08-29.0%$0.14$0.08▼$3.39$665K-0.03174,552 shs419,350 shsPTPIPetros Pharmaceuticals$0.03-2.0%$0.03$0.02▼$16.25$897K1.594.68 million shs523,260 shsZVSAZyVersa Therapeutics$0.14-7.5%$0.26$0.11▼$3.37$1.11M0.733.14 million shs33,896 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life+24.68%+29.73%+46.56%+22.29%-95.51%BPTHBio-Path-29.02%-36.00%-42.86%-59.41%-91.80%PTPIPetros Pharmaceuticals+6.67%-3.36%+6.27%-4.00%-99.66%ZVSAZyVersa Therapeutics-7.47%+16.47%-17.65%-80.06%-94.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.92+24.7%$1.41$1.14▼$73.75$321K-0.462.02 million shs60.85 million shsBPTHBio-Path$0.08-29.0%$0.14$0.08▼$3.39$665K-0.03174,552 shs419,350 shsPTPIPetros Pharmaceuticals$0.03-2.0%$0.03$0.02▼$16.25$897K1.594.68 million shs523,260 shsZVSAZyVersa Therapeutics$0.14-7.5%$0.26$0.11▼$3.37$1.11M0.733.14 million shs33,896 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life+24.68%+29.73%+46.56%+22.29%-95.51%BPTHBio-Path-29.02%-36.00%-42.86%-59.41%-91.80%PTPIPetros Pharmaceuticals+6.67%-3.36%+6.27%-4.00%-99.66%ZVSAZyVersa Therapeutics-7.47%+16.47%-17.65%-80.06%-94.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 0.00N/AN/AN/ABPTHBio-Path 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/AZVSAZyVersa Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$2.46 per share0.78$37.78 per share0.05BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/APTPIPetros Pharmaceuticals$5.11M0.18N/AN/A$4.04 per share0.01ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/ABPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%11/13/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$52.91N/A∞N/AN/A-78.22%-23.50%N/AZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%11/13/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.022.422.32BPTHBio-PathN/A0.860.86PTPIPetros Pharmaceuticals1.580.850.74ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%BPTHBio-Path5.74%PTPIPetros Pharmaceuticals12.34%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%BPTHBio-Path0.72%PTPIPetros Pharmaceuticals12.25%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life100167,000863,000Not OptionableBPTHBio-Path108.31 million5.73 millionOptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableZVSAZyVersa Therapeutics27.94 million4.86 millionNot OptionableBON, PTPI, ZVSA, and BPTH HeadlinesRecent News About These CompaniesZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKDSeptember 3, 2025 | msn.comZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ...September 3, 2025 | finance.yahoo.comZyVersa Therapeutics Initiates Phase 2a Clinical Trial for Cholesterol Efflux Mediator™ VAR 200 in Diabetic Kidney Disease PatientsSeptember 3, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ProgressionSeptember 3, 2025 | globenewswire.comZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq DelistingAugust 20, 2025 | msn.comZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last yearAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...August 14, 2025 | bakersfield.comBZyVersa Therapeutics highlights data on role of lipotoxicity in DKDAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its ProgressionAugust 14, 2025 | globenewswire.comZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product DevelopmentAugust 13, 2025 | quiverquant.comQZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building MilestonesAugust 13, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressJuly 21, 2025 | globenewswire.comZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comWhy Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?July 8, 2025 | benzinga.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross ProceedsJuly 8, 2025 | globenewswire.comZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII AmyloidosisJuly 8, 2025 | finanznachrichten.deZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII AmyloidosisJuly 8, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Energy Stocks to Gain Exposure to the Carbon Capture BoomBy Leo Miller | August 16, 2025BON, PTPI, ZVSA, and BPTH Company DescriptionsBon Natural Life NYSE:BON$1.92 +0.38 (+24.68%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.78 -0.14 (-7.08%) As of 09/9/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Bio-Path NASDAQ:BPTH$0.08 -0.03 (-29.02%) As of 09/9/2025 03:57 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (-2.04%) As of 09/9/2025 03:57 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.ZyVersa Therapeutics NASDAQ:ZVSA$0.14 -0.01 (-7.47%) As of 09/9/2025 03:56 PM EasternZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
